CapForce Inc. · OTC:CFOR
CapForce — Opgen — Investor Presentation (August 2020)
29 slides from CapForce's investor presentation, Aug 20, 2020
Slide 1: OpGen Corporate Overview
August 2020 OpGen Corporate Overview
Slide 2: Forward looking statements disclaimer
Forward looking statements disclaimer ©2020 OpGen , Inc. 2 This presentation contains forward - looking statements that are subject to many risks and uncertainties . These statements , among other things , relate to our business strategy , goals and expectations concerning our products , future oper
Slide 3: Recent newsflow
Recent newsflow • Curetis has successfully obtained CE IVD marking of its proprietary, rapid SARS CoV - 2 PCR test kit – expect to launch in Europe in Q3 and cease distribution of BGIO kit immediately • OpGen announced a strategic co - promotion partnership with Menarini Silicon Biosystems to market
Slide 4: OpGen and its group companies: Striving to innovate molecular microbiology
OpGen and its group companies : Striving to innovate molecular microbiology ©2020 OpGen, Inc. 4 Fast Comprehensive Smart Easy Rapid Pathogen Detection For Life Threatening Infections Broad Pathogen & Antimicrobial Resistance (AMR) Marker Coverage AI - Powered AMR Prediction & Bioinformatics Sample -
Slide 5: Combined company's portfolio: Synergistic products & capabilities
Combined company’s portfolio : Synergistic products & capabilities ©2020 OpGen, Inc. 5 Unyvero Platform & Syndromic Tests Acuitas Tests & Acuitas Lighthouse Global Commercial Presence Ares Genetics NGS & Bioinformatics Unyvero FDA - cleared platform for lower respiratory tract infection (LRT & LRT B
Slide 6: Strategic rationale and benefits
Strategic rationale and benefits ©2020 OpGen, Inc. 6 Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global c
Slide 7: Combined company to address unmet clinical needs and large market opportunities
Combined company to address unmet clinical needs and large available market opportunities ©2020 OpGen, Inc. 7 U.S. and European markets with ~10 million hospitalized patients annually addressed through hospital - focused sales channels Pneumonia (HPN/LRT) Implant and Tissue Infections (ITI) Blood Cu
Slide 8: Strategic rationale and benefits
Strategic rationale and benefits ©2020 OpGen, Inc. 8 Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global c
Slide 9: We help fight the COVID global pandemic
We help fight the COVID - 19 global pandemic ©2020 OpGen, Inc. 9 SARS CoV - 2 Kit with PULB, PCR - compatible universal lysis buffer, COVID - 19 pneumonia co - infections CE - IVD marked SARS CoV - 2 Kit with PULB HPN/LRT cartridges CE marked & FDA cleared for lower respiratory tract infections such
Slide 10: Sample-to-answer high-throughput testing capabilities
Sample - to - answer high - throughput testing capabilities ©2020 OpGen, Inc. 10 Innovating molecular microbiology through proprietary platforms and content Striving for molecular microbiology innovation MDx Platforms MDx Content Low - to high - plex PCR Broad range of sample types Unyvero A50 High
Slide 11: Broad Unyvero cartridge portfolio
Broad Unyvero cartridge portfolio ©2020 OpGen, Inc. 11 HPN / LRT BAL* Hospitalized Pneumonia / Lower Respiratory Tract Infections ITI Implant & Tissue Infection IAI Intra - Abdominal Infection BCU Blood Culture UTI Urinary Tract Infection * Unyvero LRT / LRT BAL are FDA cleared – all other products
Slide 12: Unique and differentiated syndromic panels
Unique and differentiated syndromic panels ©2020 OpGen, Inc. 12 Cartridge Indication area Number of targets covered Sample types Clearance status HPN** Severe cases of Pneumonia 48 targets****, pathogens (29) and antibiotic resistance markers (19) Sputum, broncho - alveolar lavage, tracheal aspirate
Slide 13: Current U.S. product offerings: Unyvero LRT & LRT BAL
Current U.S. product offerings : Unyvero LRT & LRT BAL Providing Clear Direction • FDA - cleared , sample - to - answer , in less than 5 hours with just about 2 min hands - on time • Direct from native specimen , FDA - cleared for bronchoalveolar lavage fluids and tracheal aspirates • Multiplex PCR
Slide 14: Current U.S. product offerings: Acuitas AMR Gene Panel
Current U.S. product offerings : Acuitas AMR Gene Panel* Detects most deadly superbugs E. coli, K. pneumoniae , P. mirabilis , P. aeruginosa , E. faecalis ©2020 OpGen, Inc. 14 Panel available for RUO in outbreak monitoring and epidemiology settings ( for isolates FDA clearance decision pending ) – a
Slide 15: Unyvero A30 RQ rapid testing platform in development
Unyvero A30 RQ Rapid sample - to - answer testing platform in development Key Design Features • Fully integrated , closed , sample - to - answer MDx platform • Universal real - time PCR technology for low - to mid - plex testing • Flexible cartridge fluidics for numerous chemistries and assay format
Slide 16: Strategic rationale and benefits
Strategic rationale and benefits ©2020 OpGen, Inc. 16 Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global
Slide 17: Ares Genetics & ARESdb
Ares Genetics & ARESdb * ©2020 OpGen, Inc. 17 Bioinformatics powerhouse with industry - leading proprietary AI - powered AMR knowledgebase for molecular microbiology Global ARESdb Database • Unique Knowledgebase on Antibiotic Resistance Markers building on SIEMENS Microbiology Strain Collection • De
Slide 18: Acuitas Lighthouse: Diagnostics data management platform
Acuitas Lighthouse ® : Diagnostics data management platform for antibiotic resistant pathogens * ©2020 OpGen, Inc. 18 Rapid molecular antibiotic resistance prediction Cloud - based bioinformatics platform powers our ability to trace AMR in real - time with the potential to change the landscape of cl
Slide 19: Strategic rationale and benefits
Strategic rationale and benefits ©2020 OpGen, Inc. 19 Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global
Slide 20: Dual commercial model
Dual commercial model Multiple products to same hospital call points via same sales channel to drive synergies and cost efficiencies ©2020 OpGen, Inc. 20 Leveraging synergies from our now combined commercial team structures Expanding global commercial reach though direct sales in U.S. and via global
Slide 21: Pan-European distribution via Menarini
Pan - European distribution via Menarini ©2020 OpGen, Inc. 21 Currently 11 EU countries – option to expand relationship to further EMEA markets and additional product lines Menarini Diagnostics & Curetis Collaboration ( since Q1 - 2019) • Covers entire Unyvero A50 product line • Currently covered co
Slide 22: OpGen and MSB Co-Market COVID Antibody Test Kit
OpGen and MSB Co - Market COVID - 19 Antibody Test Kit ©2020 OpGen, Inc. 22 Co - Promotion Agreement • OpGen is authorized to market and promote such products in the United States, Canada, and Mexico under a strategic co - promotion agreement entered into by OpGen and MSB • COVID - 19 related produc
Slide 23: Strategic rationale and benefits
Strategic rationale and benefits ©2020 OpGen, Inc. 23 Well positioned to capitalize on global opportunities in infectious disease and rapid AMR detection Proprietary molecular diagnostic tests and platforms Premier AI - powered bioinformatics solutions for multi - drug resistance diagnostics Global
Slide 24: Financial considerations as of June 30, 2020
Financial considerations as of June 30, 2020 Proforma Combined Revenue: • FY 2018 revenues of $4.5 • FY 2019 revenues of $6.0 million • H1 2020 revenues of $2.8 million Reported Revenue : • 2Q 2020 revenues of $1.2 million • H1 FY revenues of $1.8 million (excluding $1.0 million of Curetis revenue d
Slide 25: Operations and other key items
Operations Other Key Items • 20,000 sq. ft. Corporate HQ and FDA registered R&D/ manufacturing facility in Gaithersburg, Maryland, USA • 17,000 sq . ft . FDA registered R&D, operations and G&A facility in Holzgerlingen, southern Germany • 17,000 sq . ft . FDA registered manufacturing facility in Bod
Slide 26: OpGen Inc. executive leadership team and board
OpGen Inc. executive leadership team and board 26 Oliver Schacht, Ph.D . Timothy (Tim) C. Dec Johannes (Jan) Bacher William (Bill) Rhodes (Chairman) Evan Jones Mario Crovetto Don Elsey Prabhavathi Fernandes, Ph.D . Oliver Schacht, Ph.D. (CEO) Chief Executive Officer: Chief Financial Officer: Chief O
Slide 27: Upcoming milestones, newsflow & catalysts
Upcoming milestones , newsflow & catalysts Unyvero & Acuitas ® rapid molecular tests • Final study data from Karolinska Institutet, Stockholm, Sweden in COVID - 19 bacterial pneumonia co - infection clinical study • FDA clearance decision Acuitas ® AMR Gene Panel (isolates) • USA commercial updates
Slide 28: Contact info
Contact info OpGen Inc. (Global HQ) 708 Quince Orchard Road Gaithersburg , MD 20878 USA +1 301.869.9683 [email protected] ©2020 OpGen, Inc. 28 Curetis GmbH Max - Eyth - Str. 42 71088 Holzgerlingen, Germany +49 (0)7031 49195 - 10 [email protected] Ares Genetics GmbH Karl - Farkas - Gasse
Slide 29: Thank You!
Thank You ! 29 ©2020 OpGen, Inc .